Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma.

The Journal of clinical endocrinology and metabolism - 1 Mar 2005

Wolkersdörfer Gernot W, Marx Christian, Brown John, Schröder Sabine, Füssel Monika, Rieber E Peter, Kuhlisch Eberhard, Ehninger Gerhard, Bornstein Stefan R

Abstract excerpt

A distinctive feature of malignant adrenocortical neoplasms is decreased major histocompatibility complex (MHC) class II molecule expression. However, it is unknown whether there exists a restriction to certain MHC genotypes and whether this involves alterations of the Fas/Fas ligand system and thereby affects tissue homeostasis. Therefore, MHC class II phenotype and genotype and expression patterns of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Neoplasms
Share to Adrenocortical Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fas Ligand Protein

Share to fas Receptor

Share to HLA-DR Antigens

Share to HLA-DRB1 Chains

Share to Immunohistochemistry

Share to Membrane Glycoproteins

Source

Identifiers

PMID: 15585555
DOI: 10.1210/jc.2004-1406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma.PMID 15585555Read ↗

The Steroidal Profile Modulates Adaptive Immune Response and Prognosis in Adrenocortical Carcinoma: Analysis of TCR and BCR Repertoires.Semantic proximity Read ↗

[Pathology of adrenocortical tumors: review and recent data].Semantic proximity Read ↗

Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcomeSemantic proximity Read ↗

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studySemantic proximity Read ↗

Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors.Semantic proximity Read ↗

Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumorsSemantic proximity Read ↗

Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.Semantic proximity Read ↗

Dissecting Morphological and Molecular Heterogeneity in Adrenocortical Carcinoma.Semantic proximity Read ↗

Myxoid adrenocortical neoplasms: a study of the clinicopathologic features and EGFR gene status of ten Chinese cases.Semantic proximity Read ↗

Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.Semantic proximity Read ↗

Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinomaSemantic proximity Read ↗

Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.